Investor PortalJLS logo

The JLS Fund: Investments at the Intersection of Psychedelics & Technology

JLS was formed to invest in the exciting intersection of science, technology and neurology, leveraging the enormous potential of plant-based and psychedelic medicines to heal illness and enhance wellness. We focus on the development of drugs for intractable mental and physical conditions and the enabling technology and tools that can accelerate and enhance the delivery of those therapies.

arrow

Investments & Advisories

Investments

Mindmed

MindMed discovers and develops psychedelics inspired medicines

Gilgamesh

Gilgamesh is developing the next generation of central nervous system drugs derived from psychedelics

Diamond therapEutics

Diamond Therapeutics develops psilocybin based medicines while mitigating side effects

Micro Systemics

Myco systemics

Myco Systemics' mission is to provide systemic scalable myco-cultivation infrastructure to enable producers to meet the demands of the exploding global mushroom market

Tactogen

Tactogen is a public benefit cooperation whose goal is to make transformative medicines safer, more effective, and more accessible

MINDLEAP HEALTH

Mindleap's integration coaches help you to understand and embody the most important parts of your Psychedelic trip, allowing you to create lasting personal transformation.

atai life sciences

ATAI is committed to developing more effective and potentially disease-modifying mental health treatments by researching both psychedelic and non-psychedelic compounds.

universal ibogaine

Universal Ibogaine's mission is to bring proven Ibogaine based clinical treatment protocol to the world and help solve the international opioid crisis

Good Cap Logo

GoodCap Wellness

Harnessing the powerful medicinal and nutritional benefits of mushrooms. The world needs better approaches to mental health and overall well-being. GoodCap is developing effective mushroom-based treatments that open new pathways to a healthier future.

Gwella

GWELLA

Gwella's focus is on developing transformative consumer brands, products and technologies aimed at elevating people's health and wellbeing.

LUCID NEWS

Lucid News provides informed, honest and transparent journalism that covers the growing integration of psychedelics into society and their broad implications for human wellness.

orthogonal

Orthogonal's mission is to give people access to nature’s most effective health solutions while setting the standard of a new “Farma”: Food as Medicine.

double blind

.

A digital media company covering psychedelics and all they intersect with, from healthcare disparities to the climate crisis

Wesana logo

wESANA

.

A life sciences company whose mission is to treat traumatic brain injury and other mental health ailments using psilocybin and other natural therapies.

Press

forbes logo

Benzinga

Why Would Anyone Invest In The Psychedelics Medicine Market?

Psilocybin Alpha

psilocybin alpha

Interview with Simeon Schnapper, Managing Partner of JLS

forbes logo

Forbes

Why Investors Are Bullish About Psychedelics

forbes logo

Psychedelic Finance

Interview with Jeff Siegel, Managing Partner of JLS Fund

Terpenes and Testing

terpenes and testing

Ibogaine: The ‘Strange Kind of Drug’ for Transcending Addiction

Bloomberg

Bloomberg

Psychedelics Replace Pot as the New Favorite Edgy Investment

forbes logo

Benzinga

Why The Psychedelics Market Is NOT Cannabis 2.0

Business Insider

business insider

Investors are pouring millions into startups that are developing magic mushrooms as medications for conditions like depression and PTSD

Business Insider

Business Insider

Meet the top 14 psychedelics startups raising the most cash to develop new ways of treating depression, addiction, and more

Green Market Report

green market report

Psychedelic Industry Continues To Draw Millions In Investments

The Green Rush

the green rush

Lindsay Hoover and Simeon Schnapper, Managing Partners of JLS Fund

Press

Speaking & Panel Appearances

Investments

Moderated Conferences

INAUGURAL MICRODOSE CONFERENCE

Moderated by Simeon Schnapper

CEO Panel #1: Srinivas Rao MD, PhD- (ATAI) Payton Nyquvest (Numinus), Judy Blumstock (Diamond Therapeutics) Shlomi Raz (Eleusis), Ronan Levy (FieldTrip)

CEO Panel #2: Jackee Stang (Delic), Todd Shapiro (Red Light Holland), Jonathan Sporn MD (Gilgamesh), Martijn Schirp (Synthesis)

The Mushroom: Paul Stamets (Simeon’s hero), Gary Costner (Mycosystemics), David Kurth (Sporing Company), Eric Osborne (MycoMeditations), Dr K Mandrake (Psilocybin Mushroom Bible)

Venture Capital & Funding: Robert Laurie (MAPS), Florian Brand (ATAI), Mark Hazan (Tabula Rasa) Matthew Nordgren (Arcadian Fund), Bek Muslimov (Leafly Tunnel), Richard Skaife (TCF VC)

Watch
Microdose

Know Thyself: Psychedelics & Spirituality

Moderated by Simeon Schnapper

• The State and Future of Psychedelic Therapist Training with Elizabeth M. Nielson, PhD
• MDMA and Transformative Psychedelic Therapy with Dr. Rick Doblin
• MDMA-assisted Psychotherapy: Beyond Symptom Reduction with Dr. Ingmar Gorman
• Healing What Divides Within with Dr. Willa Hall
• PANEL Q&A: MDMA Therapy with Dr. Hall & Dr. Gorman
• MDMA-Assisted Psychotherapy & Social Anxiety Disorder with Dr. Jason Luoma
• MDMA for Couples Therapy Love & Connection Love and connection with Dr. Anne Wagner
• PANEL Q&A: MDMA Therapy with Dr. Luoma & Dr. Wagner
• The Future of MDMA-Assisted Therapy & Availability Dr. Corine de Boer
• Use of Natural Mind-Altering Substances: Cannabis with Dr. Darryl Hudson
• Psychedelics and Depression with Dr. Xiaojue Hu

All ticket proceeds go to Tibet House.

Watch
Tibet House logo

Meet the team

Lindsay Hoover
LinkedIn
LINDSAY HOOVER
Managing partner
jefferey siegel
LinkedIn
JEFFREY SIEGEL
Managing partner & investor relations
simeon schanpper
LinkedIn
SIMEON SCHNAPPER
Managing partner
ahbi vase
LinkedIn
ABHI VASE
Advisor
LinkedIn
Michael Gruber
Advisor
walter greenleaf
LinkedIn
WALTER GREENLEAF
Advisor
lorne gertner
LinkedIn
LORNE GERTNER
Advisor

Contact

General Inquiries